VolitionRX Ltd VNRX 深 沪
已收盘 03-27 16:00:00 美东时间
0.1966
+0.004
+1.87%
华盛通- 最 高0.2025
- 今 开0.1905
- 成交量 714.85万股
- 最 低 0.1826
- 昨 收 0.193
- 总市值 2673.76万
- 52周最高 0.94
- 市盈率 静 --
- 换手率 5.26%
- 52周最低 0.17
- 委 比 -20.00%
- 总股本 1.36亿
- 历史最高 9.28
- 量 比 0.21
- 振 幅 10.31%
- 历史最低 0.17
- 每 手 1
- 风险率 0.18%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多VolitionRx To Highlight Use Of Its Nu.Q Cancer Assays In Management Of Lung Cancer Patients At European Lung Cancer Conference
VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announces the presentation of an abstract at the European Lung Cancer Conference (ELCC) in Copenhagen, Denmark this week. The poster
03-26 20:20
VolitionRx announces ELCC abstract on Nu.Q lung cancer blood test; study links preoperative H3K27Me3-nucleosome levels to recurrence-free and overall survival risk stratification
VolitionRx announces ELCC abstract on Nu.Q lung cancer blood test; study links preoperative H3K27Me3-nucleosome levels to recurrence-free and overall survival risk stratification Volition announced that an abstract on using its Nu.Q Cancer assays for lung cancer patient management was presented as a
03-26 20:17
Volition Announces Detection of Over 95% of Early-Stage Cancers
Blinded validation cohort achieves over 95% sensitivity for stage I & II cancers with 95% specificity Capture-Seq™ Targets $36 Billion TAM in Early Cancer Detection and MRD. HENDERSON, Nev.,...
03-25 20:17
VolitionRx Achieves >99% Pure Tumor-Derived DNA Isolation With Novel ChIP-Seq Liquid Biopsy Technology, Advancing Early Cancer Detection
Targets $36 Billion TAM in Early Cancer Detection and MRD.Company in active discussions with global diagnostic leaders to accelerate commercialization.HENDERSON, Nev., March 18, 2026 /PRNewswire/ -- VolitionRx Limited
03-18 20:21
BRIEF-Volition Reports Breakthrough In Liquid Biopsy Achievement Of Over 99% Purity In Isolating Cancer Dna
BRIEF-Volition Reports Breakthrough In Liquid Biopsy Achievement Of Over 99% Purity In Isolating Cancer Dna March 18 (Reuters) - VolitionRX Ltd VNRX.A : VOLITION REPORTS BREAKTHROUGH IN LIQUID BIOPSY: ACHIEVEMENT OF OVER 99% PURITY IN ISOLATING CANCER DNA Source text: ID:nPnc57dkxa Further company c
03-18 20:20
VolitionRx reports clinical validation results showing 49/49 cancers detected with no false positives
VolitionRx reports clinical validation results showing 49/49 cancers detected with no false positives Volition reported an updated manuscript describing a two-step method that generated sequencing datasets with more than 99% purity for circulating tumor-derived DNA from blood samples of cancer patie
03-18 20:17
VolitionRx Completes All Validation And Verification Of Chemiluminescent Immunoassay Version Of Nu.Q Vet Cancer Test With Fujifilm Vet Systems in Japan
VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announces the completion of all validation and verification of the chemiluminescent immunoassay (ChLIA) version of its Nu.Q®
03-06 21:12
Volition Announces First Ever Automated Nu.Q® Vet Cancer Test with Fujifilm Vet Systems
HENDERSON, Nev., March 6, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the completion of all validation a...
03-06 21:10
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Larimar Therapeutics (NASDAQ:LRMR) shares moved upwards by 58.4% to $5...
02-26 01:05
VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution
HENDERSON, Nev., Feb. 25, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is pleased to provide a consolidated update on the...
02-25 21:10
